Live Breaking News & Updates on Incretins

Stay updated with breaking news from Incretins. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Beyond Glucose Control - The Expanding Role of Incretins in Diabetes and Obesity Management

In this MEDcast episode, Diana Isaacs, PharmD, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, interview Dr Juan Frias to explore the mechanism of GLP-1 and GIP agonists in diabetes and weight management and examine key findings from clinical trials for the latest GLP-1/GIP dual agonist. ....

Diana Isaacs , Natalie Bellini , Juan Frias , Beyond Glucose Control , Expanding Role , Obesity Management , Glucose Control ,

Treating Obesity: Will New Miracle Drugs End the Crisis?

Doctors and researchers have been trying to end the obesity epidemic for decades and have failed. Can a new set of effective drugs finally succeed? Second in a 3-part series on the obesity crisis. ....

San Francisco , United States , Cornell University , New York , James Hill , Rockefeller University , Samuel Klein , Randy Seeley , Dariush Mozaffarian , Robert Lustig , Eli Lilly , Gary Foster , Louis Aronne , Wake Forest Baptist Health Weight Management Center , Washington University School Of Medicine , University Of Pennsylvania , Tufts School Of Medicine , Nutrition Obesity Research Center , National Institutes Of Health , University Of Alabama At Birmingham , Michigan Nutrition Obesity Research Center , University Of California , Novo Nordisk , Weill Cornell Medicine , Washington University School , Weight Loss ,

Tirzepatide's Benefits Go Beyond GLP-1 Agonist Effects

Tirzepatide s agonist effect on GIP receptors of isolated pancreatic islet cells appears responsible for a good portion of the drug s effects beyond its GLP-1 receptor agonism. ....

Duke University , North Carolina , United States , Eli Lilly , Novo Nordisk , German Center , Diabetes Research In Neuherberg , Diabetes Research , Structure Therapeutics , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Incretin Hormones , Body Mass Index Bmi , Esearch In Diabetes , Ndocrine System , Match Day , Watch Application , Atch Medical Students ,

'Staggering' Weight Loss With Tirzepatide

Over 60% of participants achieved the weight-reduction target of 20% or higher and had improved body composition in a phase 3 trial of tirzepatide in overweight/obesity. ....

New York , United States , Louis Aronne , Gabriella Lieberman , Eli Lilly , Drug Administration , European Congress On Obesity , Weight Control Center , Israeli Center , Sheba Medical Center , European Medicines Agency , Comprehensive Weight Control Center , Weill Cornell Medicine , New England Journal , Weight Management , Medscape Medical , Body Composition , Bariatric Surgery , Obesity Surgery , Weight Loss Surgery , Urgery Weight Loss , Weight Loss , Body Mass Index Bmi , Incretin Hormones , Glp 1 Receptor Agonists , Glucagon Like Peptide 1 Receptor Agonists ,

Obesity Drug With Swallowable Balloon Boosts Weight Loss

A combination of a swallowable Allurion gastric balloon and liraglutide delivers higher weight loss (around 19% after mean 4 months) than use of separate treatments. ....

Adelardo Caballero , Clinica Nuova Villa Claudia , Roberta Ienca , Institute Of Obesity , European Congress On Obesity , Novo Nordisk , Allurion Program , Allurion Balloon , European Congress , Medscape Medical , Weight Loss With Balloon , Weight Loss , Weight Management , Glp 1 Receptor Agonists , Glucagon Like Peptide 1 Receptor Agonists , Incretin Hormones , Body Mass Index Bmi ,